Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the hypothesis that sotagliflozin (SGLT1/2 inhibitor) and
ambrisentan (ERA) combination therapy augments nephroprotection and mitigates fluid retention
and ketogenesis in people with T1D through complementary and synergistic mechanisms of
actions.
Phase:
Phase 2
Details
Lead Sponsor:
University Medical Center Groningen
Collaborators:
Juvenile Diabetes Research Foundation Lexicon Pharmaceuticals